President Trump speaks during a press briefing with FDA commissioner Stephen Hahn (left) and White House coronavirus response coordinator Deborah Birx (right) of the coronavirus task force, at the White House, Thursday, March 19, 2020, in Washington. (AP Photo/Evan Vucci)

March 20, 2020 07:31 AM EDTUpdated 08:30 AM

Coronavirus

Opinion

No, Mr. President, you can’t just order up outbreak meds with the snap of your fingers

Donald Trump was in classic freestyle speaking mode on Thursday as he talked up the immediate production of drugs that can fight the new coronavirus …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

No, Mr. President, you can’t just order up outbreak meds with the snap of your fingers

This article is available only to Premium subscribers

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

No, Mr. Pres­i­dent, you can’t just or­der up out­break meds with the snap of your fin­gers

This article is available only to Premium subscribers

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

No, Mr. President, you can’t just order up outbreak meds with the snap of your fingers

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence